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Hepatitis B virus (HBV) infects from 6 to 14% of HIV-infected individuals. Concurrent HIV/HBV infection occurs due to
the overlapping routes of transmission, particularly sexual and parenteral. HIV-infected patients that have acute
hepatitis B have six times greater risk of developing chronic hepatitis B, with higher viral replication, rapid progression
to end-stage liver disease and shorter survival. The coinfection is also associated with poor response to hepatitis B
treatment with interferon-alpha and increased liver toxicity to the antiretroviral therapy. Herein, we describe the case
of a 35-year-old man who engages in sex with men and presented with newly diagnosed HIV-1, serological markers for
acute hepatitis B and progression to chronic hepatitis B infection (HBsAg+ > 6 months, high alanine aminotransferase
levels and moderate hepatitis as indicated by liver biopsy). Lacking indication of antiretroviral treatment (CD4
768 cells/mm3), he was treated with pegylated-interferon alpha2b (1.5 mg/kg/week) by subcutaneous injection for
48 weeks. Twelve weeks after treatment, the patient presented HBeAg seroconversion to anti-HBe. At the end of
48 weeks, he presented HBsAg seroconversion to anti-HBs. One year after treatment, the patient maintained sustained
virological response (undetectable HBV-DNA). The initiation of antiretroviral therapy with nucleosides and nucleotides
is recommended earlier for coinfected individuals. However, this report emphasizes that pegylated interferon remains
an important therapeutic strategy to be considered for selected patients, in whom the initiation of HAART may
be delayed.
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Worldwide, an estimated two billion people have been
infected with the hepatitis B virus (HBV), more than 350
million have chronic liver infection and 34 million live
with the human immunodeficiency virus (HIV) infection
[1,2]. The prevalence of hepatitis B in HIV-infected indi-
viduals ranges from 6 to 14%, with higher rates in regions
where HBV is endemic, such as Africa and Asia [1,3]. Con-
current infection of HIV with HBV occurs because of the
overlapping routes of transmission, particularly sexual and
parenteral (injecting drug use and blood transfusion).
In Brazil, the prevalence of coinfection ranges from 5.3
to 24.3% with significant regional differences [4]. The west-
ern Amazon is considered highly endemic for hepatitis B,* Correspondence: adri36_unicamp@hotmail.com
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reproduction in any medium, provided the orin particular because of the coinfection with hepatitis Delta
virus (HDV) [1]. In addition, a recent population-based
prevalence study in Brazilian state capitals showed that all
geographical regions were considered of low endemicity
[5]. Acute hepatitis B patients with HIV infection have
six times greater risk of developing chronic hepatitis B,
with higher viral replication, rapid progression to end-
stage liver disease and shorter survival [6]. The coinfec-
tion is also associated with poor response to hepatitis B
treatment with interferon-alpha, lower rates of HBeAg
seroconversion to anti-HBe and HBsAg to anti-HBs, and
greater liver toxicity using the antiretroviral therapy
[7-10]. Since the introduction of highly active antiretro-
viral therapy (HAART), liver disease has emerged as an
important cause of morbidity and mortality in HIV-
infected individuals. Treatment of chronic hepatitis B is
based on the use of pegylated interferon or nucleosides
and nucleotides polymerase inhibitors. The internationalLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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for the treatment of HBeAg positive coinfected patients
that are non-cirrhotic and with no indication for anti-
retroviral therapy, with limited treatment duration and
probably greater chance of viral suppression after dis-
continuation [11,12].
Case presentation
We report the case of a 35-year-old male patient who
engages in sexual activity with men, followed in the
Campinas Reference Center for Sexually Transmitted
Diseases/AIDS since January 2009, with newly diag-
nosed HIV-1 and the following serological markers for
hepatitis B: surface antigen positive (HBsAg+), hepatitis B e
antigen positive (HBeAg+), antibodies to hepatitis B core
antigen positive (anti-HBc IgM+, anti-HBc IgG+), anti-
hepatitis B e antibody negative (anti-HBe-), and anti-
hepatitis B surface antigen antibody negative (anti-HBs-).
He had a steady partner who presented a diagnosis of
hepatitis B with seroconversion to anti-HBs + about four
months before the start of the monitoring service and
HIV-1 negative at diagnosis of the patient, with serocon-
version to HIV-1 positive in 2010.
On physical examination, the patient was in good general
condition and his body mass index was 24 kg/m2. His liver
was palpable at 2 cm from the right costal margin and his
spleen was palpable at 2 cm from the left costal margin.
He had no stigmata of chronic liver disease.
In February 2009, CD4+ lymphocyte (CD4) count was
718 cells/mm3, HIV-1 viral load (VL) was 9399 copies/mL,
aspartate aminotransferase (AST) was 347 IU/mL, alanine
aminotransferase (ALT) 604 IU/mL, HBsAg+, HBeAg+,
anti-HBc IgG+, anti-HBc IgM+, anti-HBe-, anti-HBs-,
antibody for hepatitis C virus (HCV) negative, and
antibody for hepatitis A (HAV) IgG+, IgM- (Table 1).Table 1 Laboratory tests performed during follow-up
Laboratory tests
Feb. 16, 2009 Oct. 13, 2009 May 13, 2
CD4 (cells/mm3) 718 768 678
HIV viral load (copies/mL) 9399 3746 2553
Hemoglobin (g/dL) 16.7 15.2 15.4
Neutrophils/mL 2236 1867 714
Platelets 103/mL 192 187 124
AST/ALT (IU/mL) 347/604 101/136 217/223
HBsAg Positive Positive –
HBeAg Positive Positive –
Anti-HBc IgG Positive Positive –
Anti-HBc IgM Positive Negative –
Anti-HBe Negative Negative –
Anti-HBs Negative Negative –The biochemical liver function test values were normal.
Upper endoscopy showed gastroduodenitis with H. pylori
positive and total abdominal ultrasound showed no
abnormality.
The patient was classified into the first stage of HIV
infection (A1), according to the Centers for Disease
Control and Prevention (CDC) criteria and acute HBV
infection. Then, it was decided to monitor the hepatitis
B progress and not initiate antiretroviral therapy.
After eight months of follow-up, the patient had the
following laboratory tests results: CD4 768 cells/mm3,
VL 3746 copies/mL, AST 101 IU/mL, ALT 136 IU/mL,
HBsAg+, HBeAg+, anti-HBc IgG+, anti-HBc IgM-, anti-
HBe-, and anti-HBs- (Table 1).
When chronic hepatitis B (HBsAg+ > 6 months) was
confirmed, a liver biopsy was performed resulting in
METAVIR score F2A2. Because of the persistence of
HBsAg, increased ALT levels and no indication of anti-
retroviral therapy, treatment was initiated for hepatitis B
with pegylated-interferon alpha2b (80 mcg), 1.5 mg/kg
once a week, by subcutaneous injection for 48 weeks.
During treatment, the patient developed moderate
neutropenia (minimum of 714 neutrophils/mL) controlled
by use of filgastrima, thrombocytopenia (minimum of
124,000 platelets/mL), nadir CD4 520 cells/mm3 and
bipolar affective disorder, stabilized on lithium carbon-
ate (Table 1). At 12 weeks of treatment, the patient
presented HBeAg seroconversion to antiHBe and nor-
malization of liver enzymes. At the end of 48 weeks of
treatment, he presented HBsAg-, anti-HBc IgG+, anti-
HBs > 1000 mIU/mL (Figure 1). In May 2012, a year after
the end of treatment, the patient showed AST 26 IU/mL,
ALT 14 IU/mL, anti-HBc IgG+, anti-HBs 148, CD4 466
cells/mm3 and HBV-DNA level < 15 IU/mL (reference
values 15 – 500.000.000 IU/mL by real time PCR).Date
010 Jul. 22, 2010 Feb. 21, 2011 Jun. 9, 2011 May 5, 2012
520 635 597 466
79 448 2536 –
14.6 14.0 15.5 –
2436 3129 2217 –
146 173 186 –
31/31 24/14 26/16 26/14
Positive Negative Negative Negative
Negative – – –
Positive Positive Positive Positive
Negative – – –
Positive – – –
Negative > 1000 716 148
Figure 1 Evolution of biochemical and serological tests before
and after treatment.
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This report describes the case of a HIV/HBV-coinfected
patient, without indication of antiretroviral therapy, who
had optimal response to treatment of chronic hepatitis B
with pegylated interferon. The patient presented rapid
HBeAg seroconversion to anti-HBe and HBsAg to anti-
HBs and sustained virological response one year after
the end of therapy.
According to the literature, HBeAg seroconversion to
anti-HBe occurs in up to 30% of monoinfected individ-
uals in use of pegylated interferon and in up to 28% of
coinfected individuals in use of conventional interferon-
alpha [8,11,13,14]. Furthermore, HBsAg seroconversion
to anti-HBs occurs in less than 10% of the monoinfected
and probably in a much smaller proportion of coinfected
individuals [15]. However, there are no published studies
that evaluate the therapeutic response to pegylated inter-
feron in a representative group of coinfected individuals.
There are few studies showing HBeAg and/or HBsAg
seroconversion in coinfected individuals, whether on
HAART (nucleoside and nucleotide polymerase in-
hibitors) or with use of interferon-alpha [16]. In the
early 1990s, the first case reporting HBsAg seroconver-
sion in HIV/HBV-coinfected patients treated with con-
ventional interferon-alpha was published [17]. Later, it
was reported a case of HBsAg seroconversion in a
HIV/HBV/HCV/HDV-coinfected patient after treatment
with pegylated interferon and ribavirin [18]. The most re-
cent report of hepatitis B surface antigen seroconversion
in a HIV/HBV-coinfected patient treated with pegylated
interferon was described by Rossetti et al. [19] in 2012,
with some similarities to our patient.
The lower probability of spontaneous loss of HBeAg
and HBsAg in HIV/HVB-coinfected individuals, as well as
lower seroconversion after treatment, may be explained by
the impairment of innate and adaptive immunity, with a
weak cellular immune response to HBV, typical of HIV-
infected patients [20,21]. As a cytokine, interferon-alphaacts inhibiting HBV replication through interaction with
viral proteins and stimulation of host cellular immunity.
Moreover, it is supposed that the best therapeutic response
in HIV/HBV-coinfected patients – avoiding antiretroviral
therapy and in non-cirrhotic individuals – may be obtained
in cases of HBeAg positive, with higher CD4 counts, lower
HBV-DNA levels, higher ALT levels, early stages of
liver fibrosis and genotype A [20-24]. Although some
authors suggest the importance of quantitative mea-
surement of HBsAg as predictor of virological response
and HBsAg seroconversion in monoinfected individuals, it
has not been proven yet in HIV/HBV-coinfected indivi-
duals [25,26]. It is known that HIV infects hepatocytes
already infected with HBV and leads to increased intracel-
lular levels of HBsAg, which could contribute to accele-
rated liver disease in these individuals. HBsAg levels could
not be quantified in this study [27].
Conclusion
Currently, the initiation of antiretroviral therapy with nu-
cleosides and nucleotides is recommended earlier for coin-
fected individuals, even in patients with higher CD4 counts
compared to HIV-monoinfected patients [11,12,28,29].
However, the pegylated interferon remains an important
therapeutic strategy to be considered for selected patients,
in whom the initiation of HAART may be delayed, aiming
at a more effective and lasting response to treatment, with
lower risk of progression to cirrhosis and hepatocellular
carcinoma, as the example of the patient described in the
present study [30].
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